Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.35 |
| ▸ | RXRA | P19793 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257430 | 0.82 | LOXL2 (0.55) | LOXLOXL2 | |
| SCHEMBL23977997 | 0.81 | CRHR1 (0.34) | CRHR1RXRAGRIN1GRIN2BCCR5 | |
| SCHEMBL25259201 | 0.81 | JAK2 (0.35) | KDM4ECYP11B1 | |
| SCHEMBL30399082 | 0.79 | OGA (0.35) | CCR5CCR1CCR8KDM4EALDH1A1 | |
| SCHEMBL25258921 | 0.78 | LOXL2 (0.50) | LOXLOXL2 | |
| SCHEMBL16642358 | 0.76 | CYP11B1 (0.46) | CRHR1RXRAGRIN1GRIN2BCCR5 | |
| SCHEMBL23977998 | 0.76 | CYP11B1 (0.46) | CRHR1RXRAGRIN1GRIN2BCCR5 | |
| SCHEMBL30992022 | 0.72 | UHRF1 (0.45) | CRHR1RXRAGRIN1GRIN2BCCR5 | |
| SCHEMBL16642357 | 0.72 | UHRF1 (0.45) | CRHR1RXRAGRIN1GRIN2BCCR5 | |
| SCHEMBL26453317 | 0.72 | RXRA (0.33) | RXRAGRIN1GRIN2BCCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-2021219594-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | CRHR1 2397/4885RXRA 955/4885GRIN1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.